Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Puma’s Nerlynx Edges Out Novartis’ Tykerb in Breast Cancer Trial

Puma Biotechnology’s Nerlynx (neratinib), in combination with Roche’s chemotherapy drug Xeloda (capecitabine), showed a treatment advantage compared to Novartis’ Tykerb (lapatinib) and Xeloda in a Phase III breast cancer study.

Read More »

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan’s Daiichi Sankyo’s met the main goal in a mid-stage study, bolstering the companies’ position in a highly competitive oncology market.

Read More »

FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

The U.S. Food and Drug Administration approved Roche’s Kadcyla (trastuzumab emtansine) for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin (trastuzumab)-based treatment.

Read More »

OncoSec and Duke Announce New Collaboration in Cancer Research

OncoSec Medical Incorporated and Duke University School of Medicine announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary Tavoplus (enhanced IL-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec’s novel intratumoral delivery system.

Read More »

U.S. FDA Approves Ibrance for Treatment of Men with HR+, HER2- Metastatic Breast Cancer

Pfizer announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application to expand the indications for Ibrance (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

Read More »

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.

Read More »

Breast Ultrasound and Cancer Detection Rates Increased Under New Laws

  Participating in the Blue Cross Blue Shield Alliance for Health Research, the study comes from Yale’s School of Public Health and School of Medicine   NEW HAVEN, Conn., March 22, 2019 /PRNewswire/ –State breast density notification laws that mandate reporting of mammogram results can prompt further screening and modestly boost cancer detection rates, say […]

Read More »

FDA approves Roche’s small cell lung cancer treatment

Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.

Read More »

FDA approves Pfizer’s biosimilar to Roche’s Herceptin

The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche AG’s blockbuster breast cancer treatment Herceptin.

Read More »

Roche’s Tecentriq and Companion Diagnostic Gets FDA Nod for Triple-Negative Breast Cancer

The U.S. Food and Drug Administration granted accelerated approval to Roche’s Genentech for Tecentriq (atezolizumab) plus chemotherapy (nab-paclitaxel) to treat unresectable locally advanced or metastatic triple-negative breast cancer in patients whose tumors expressed PD-L1.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom